Joshua R Sacher
Overview
Explore the profile of Joshua R Sacher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rohban M, Fuller A, Tan C, Goldstein J, Syangtan D, Gutnick A, et al.
Cell Syst
. 2022 Sep;
13(9):724-736.e9.
PMID: 36057257
Identifying the chemical regulators of biological pathways is a time-consuming bottleneck in developing therapeutics and research compounds. Typically, thousands to millions of candidate small molecules are tested in target-based biochemical...
2.
Zhang Y, Moran S, Allen A, Baez-Nieto D, Xu Q, Wang L, et al.
ACS Pharmacol Transl Sci
. 2022 Mar;
5(3):156-168.
PMID: 35311021
T-type voltage-gated Ca channels have been implicated in many human disorders, and there has been increasing interest in developing highly selective and potent T-type Ca channel modulators for potential clinical...
3.
Wang Y, Yang C, Sims M, Sacher J, Raje M, Deokar H, et al.
Cancer Lett
. 2022 Mar;
533:215614.
PMID: 35245627
Glioblastoma (GBM) is a highly aggressive cancer with a dismal prognosis. Constitutively active STAT3 has a causal role in GBM progression and is associated with poor patient survival. We rationally...
4.
He Y, Yang C, Wang Y, Sacher J, Sims M, Pfeffer L, et al.
Bioorg Med Chem
. 2021 Dec;
53:116533.
PMID: 34863065
Glioblastoma (GBM) is the most aggressive and treatment-refractory malignant adult brain cancer. After standard of care therapy, the overall median survival for GBM is only ∼6 months with a 5-year...
5.
Shembel A, Lee J, Sacher J, Johnson A
J Voice
. 2021 Jul;
37(6):897-906.
PMID: 34281751
Objectives/hypothesis: The objectives of this study were to (1) identify optimal clusters of 15 standard acoustic and aerodynamic voice metrics recommended by the American Speech-Language-Hearing Association (ASHA) to improve characterization...
6.
Reidenbach A, Mesleh M, Casalena D, Vallabh S, Dahlin J, Leed A, et al.
J Biol Chem
. 2020 Jul;
295(39):13516-13531.
PMID: 32723867
Prion disease is a rapidly progressive neurodegenerative disorder caused by misfolding and aggregation of the prion protein (PrP), and there are currently no therapeutic options. PrP ligands could theoretically antagonize...
7.
Hinze L, Labrosse R, Degar J, Han T, Schatoff E, Schreek S, et al.
Cancer Discov
. 2020 Jul;
10(11):1690-1705.
PMID: 32703769
Colorectal cancer is driven by mutations that activate canonical WNT/β-catenin signaling, but inhibiting WNT has significant on-target toxicity, and there are no approved therapies targeting dominant oncogenic drivers. We recently...
8.
Wagner F, Benajiba L, Campbell A, Weiwer M, Sacher J, Gale J, et al.
Sci Transl Med
. 2018 Mar;
10(431).
PMID: 29515000
Glycogen synthase kinase 3 (GSK3), a key regulatory kinase in the wingless-type MMTV integration site family (WNT) pathway, is a therapeutic target of interest in many diseases. Although dual GSK3α/β...
9.
Weiwer M, Xu Q, Gale J, Lewis M, Campbell A, Schroeder F, et al.
ACS Chem Biol
. 2018 Feb;
13(4):1038-1047.
PMID: 29485852
Schizophrenia is a severe neuropsychiatric disease that lacks completely effective and safe therapies. As a polygenic disorder, genetic studies have only started to shed light on its complex etiology. To...
10.
Epperly M, Sacher J, Krainz T, Zhang X, Wipf P, Liang M, et al.
In Vivo
. 2017 Jan;
31(1):39-43.
PMID: 28064218
Background/aim: Mitochondrial-targeted gramicidin S (GS)-nitroxide, JP4-039, has been demonstrated to be a potent radiation mitigator, and safe over a wide dose range. In addition, JP4-039 has organ-specific effectiveness when locally...